The name Clay Siegall may not stand out when being spoken. The name itself is fairly common, but there’s nothin common about the Clay Siegall who’s involved in cancer research. This guy is accomplished in more ways than one, and he has revolutionized the industry thanks to his valiant effort. Clay Siegall is a man of many talents as he is known to be an author, a motivational speaker, a scientist, a mentor and a doctor. The guy just so happens to be the president for one of the world’s top cancer research institutions. On top of that, Siegall has a Ph.D in Genetics from George Washington University, and he has a B.S. in Zoology from the University of Maryland.
Siegall’s valiant quest to fight this deadly disease started out when he was in college. His father struggled with the disease for many years, and it was devastating on his body. At that time, cancer fighting medications were very aggressive, which caused pain, sickness and amputation. Siegall set out on finding more progressive ways for dealing with the disease, which eventually led to the inception of Seattle Genetics. In 1998, Seattle Genetics made its debut, but times were tough in the beginning. The small Seattle-based company wasn’t making much of a profit. Siegall had to readdress the issue as well as readdress the situation. After brainstorming for ideas, Siegall brought in a talented team of salesmen. This implementation would eventually lead to success because this team was securing 7-fugure deals on a consistent basis.
As of today, Seattle Genetics earn its revenue through multiple channels. This includes licensing its own technologies, providing production partnerships and selling its proprietary medications. Seattle Genetics’ ADCETRIS drug has brought in $350 million by itself, and it is one of the most successful cancer fighting medications on the market today. Clay Siegall has done an extraordinary job over the years and it doesn’t look like he’s slowing down anytime soon.
Clay Siegall was recently appointed to Minra Therapeutics’ Board of Directors. Minra is a biotechnology firm, which focuses on the advancement and commercialization of pharmaceutical products. Siegall will serve as an external director on the firm’s board. The firm’s chief executive officer and president, Dr. Paul Lammers expressed his delight at Siegall’s appointment. The success that he has had within the industry will help open new doors for Minra.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Minra has made a name for itself through the advancement of a MicroRNA-based therapy, which is used in cancer treatment. Dr. Siegall himself expressed his delight with the appointment. He looks forward to using his research to enhance cancer research. The experience that he has had in building biotechnology firms will similarly help in advancing programs that benefit cancer patients.
Minra Therapeutics has created a niche for itself in the industry due to its groundbreaking products. It has a highly trained team of in-house scientists, who have helped it to build an impressive intellectual property portfolio. The firm has grown incredibly due to the networks that it has formed within and beyond the industry. Its board of directors is composed of proven industry heads, whose experience has been of great benefit to the firm.
Dr. Siegall in Brief
He is regarded as one of the most successful biotechnologists of his generation. Dr. Clay Siegall started Seattle Genetics in 1998. He wanted to advance cost-effective cancer therapies. The leadership that he has provided throughout the years has helped the company to build a highly diversified network. Seattle Genetics boasts an extraordinary product portfolio. It is credited with advancing anti-body based cancer therapies, which are used in more than 70 countries.
The firm is synonymous with ADCETRIS, which is its flagship commercial product. It was approved in 2011 and has gone on to become the one of the best cancer therapies. To fund Seattle Genetics’ research activities, Dr. Siegall has used his unique fundraising skills to raise more than 675 million dollars on behalf of the firm. Due to the legendary status that he has within the industry, Clay sits on the boards of different companies. He is also a publisher, with over 70 publications under his name.